C hronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disabling disease with an incompletely understood autoimmune etiology. Differentiating the condition from other neurological diseases can be challenging and appropriate treatment is often delayed. Intravenous immunoglobulin (IVIg), plasmapheresis, corticosteroids and subcutaneous immunoglobulin (SCIg) have all been demonstrated to be beneficial in placebo-controlled, randomized clinical trials. Corticosteroids, including methylprednisolone and dexamethasone are effective and frequently used in CIDP but their long-term use is limited by side effects. One of the most commonly prescribed treatments for CIDP is IVIg which diminishes inflammatory processes and prevents disease progression. Treatment with IVIg has proven effective in randomized, double blind, placebo controlled, clinical trials and the results support its use in CIDP. For some patients, the benefit of IVIg, is limited by the frequency of infusions and systemic side effects such as flu-like symptoms, headache, and nausea. Other effective treatments for CIDP include corticosteroids that are associated with serious side effects in long-term use and plasmapheresis which requires specialized facilities. More recently, SCIg has been demonstrated in double blind, placebo-controlled studies to be effective for maintenance use in CIDP in patients whose disease has been controlled by IVIg. In a large clinical trial, 0.2 g/kg and 0.4 g/kg body weight doses of 20% SCIg equivalent to 1 mL/kg or 2 mL/kg, respectively, administered weekly, demonstrated efficacy in CIDP and were well tolerated. Immunomodulating treatments such as cyclophosphamide, mycophenolate mofetil and rituximab have also shown efficacy in select populations with CIDP.
The condition usually presents as weakness in the arms and legs, balance/ gait impairment, tingling, numbness, and loss of tendon reflexes. [2] [3] [4] It can be relapsing or progressive and the available treatments have variable efficacy in different patients. 5, 6 The symptoms of CIDP cause considerable burden for patients and their families and can cause loss of function and diminished quality of life (QoL). 1, 5, 7 CIDP occurs in individuals of all ages but is more prevalent in men and in people over 60 years of age. 3, 8 The condition has an estimated incidence of 1.6/100,000/year (1.9-7.7/100,000) 9 and an estimated prevalence of up to 8.9/100,000 (depending on criteria used to define the disease). 9 CIDP may be slightly more common in patients with diabetes, though this has not been confirmed in population based studies. 9 The infrequency of the condition means that many physicians and even neurologists will rarely see a case and may have difficulty differentiating it from other neurological conditions. Correct diagnosis and appropriate treatment may consequently be delayed. 10 There are multiple subtypes of CIDP and it may actually be a spectrum of conditions rather than a single disorder. 11, 12 The variable presentation and course of the disease can make it difficult to diagnose and causes difficulties in assessing clinical trial endpoints. 5, 13, 14 In addition, there is currently a lack of any reliable biomarker for CIDP diagnosis and there is a substantial need for clearer diagnostic guidelines. 6 Many different criteria for the diagnosis of CIDP have been published and contribute to the variable incidence and prevalence reported in different publications. 5, 6, 13, 14 US NEUROLOGY Despite these challenges, CIDP is a treatable condition. Effective therapies are available and new ones are being developed. Prompt diagnosis and initiation of treatment early in the course of the neuropathy are critical to prevent irreversible disability. 5 
Current treatments for chronic inflammatory demyelinating polyneuropathy Intravenous immunoglobulin
There are a number of therapeutic options for treating CIDP, each with advantages and disadvantages. Differing response to therapy, medical comorbidities, side effects, and logistical factors all contribute to treatment decisions for any individual patient.
One of the most commonly prescribed and effective treatments for CIDP is intravenous immunoglobulin (IVIg). This is a well-established treatment that is widely considered first-line therapy in CIDP in patients without contraindications. 5, [15] [16] [17] [18] The mechanism by which IVIg works in CIDP is not fully understood but is thought to act through multiple mechanisms. It has effects on B cells and antibodies (e.g. anti-idiotype mechanisms against pathogenic antibodies), complement (inhibiting complement activation), macrophage activity (Fc receptor blockade of macrophage activation), cytokine secretion, and leukocyte migration. 19 These actions diminish inflammation and demyelinating processes and consequently prevent disease progression.
A number of studies have demonstrated the efficacy of IVIg. 15 There are limitations and side effects associated with use of IVIg in patients with CIDP. As IVIg levels fall after as little as 2 weeks, efficacy can wane. 22 Some patients experience 'wearing-off' that can occur before their next scheduled IVIg treatment. 22 Optimized or personalized IVIg regimens may be needed to reduce 'wear-off' and maintain efficacy. 23, 24 Other limitations of IVIg are related to logistical issues of intravenous administration. Dosing can take at least 2-4 hours to administer, must be dosed every 3-4 weeks, and requires the presence of a healthcare professional in the hospital, infusion center, or home. 17 Common with the procedure, it tends to be used where corticosteroids or IVIg are not sufficiently effective or cannot be tolerated. 37, 38 Some patients who respond initially to IVIg but later fail to respond adequately may improve on the combination of IVIg and plasmapheresis. 39, 40 Other treatments
A variety of other agents have been used as experimental treatments for CIDP, especially for refractory disease. 41 Mycophenolate mofetil (Cellcept®, Genentech, South San Francisco, CA, US) has been assessed in several small non-randomized studies and is sometimes used as steroid-sparing therapy. 37, 42 Intravenous pulsed cyclophosphamide, has shown benefits in treating CIDP, including complete remission in 11/15 patients in one small study. 43 High-dose cyclophosphamide (200 mg/kg), without stem cell rescue, also provided long term remissions and notable QoL improvements, in some patients refractory to standard treatment for CIDP. 44, 45 Cyclophosphamide has significant short-and long-term side effects, including infection risk, effects on fertility and long-term increased risk of malignancy, so it is typically reserved for only the most severe and refractory disease. There are no placebo-controlled studies, demonstrating benefit of rituximab, the anti-CD20 monoclonal in CIDP, but rituximab has been beneficial in patients with CIDP associated with hematologic disorders, and has been described to be effective in a number of case reports and series. [46] [47] [48] [49] Rituximab has also been reported to be effective in the recently described IgG4 paranodal antibody variants of CIDP, with neurofascin 155 and contactin 1 antibodies, which often respond poorly to IVIg. 50, 51 Randomized, double-blind, placebo-US NEUROLOGY controlled studies of methotrexate, fingolimod and beta interferon did not show benefit beyond placebo in CIDP. [52] [53] [54] Autologous hematopoietic stem cell transplantation is another experimental approach to treat CIDP 41, 55 and several case reports and case series have reported promising efficacy. In one study (n=6) longterm efficacy was sustained from 6-18 months after transplant. 56 Another study (n=11), reported significant improvements in INCAT scores within 2-6 months after treatment that was sustained throughout follow-up with a manageable complication profile. 57 Some patients despite initial improvement after autologous stem cell transplants, later relapse. 58 There is significant morbidity and risk of death with hematopoietic stem cell transplantation, so this has been reserved as treatment for only the most refractory cases. There is currently an ongoing clinical trial to better assess efficacy of stem cell transplantation as a treatment in CIDP (ClinicalTrial.gov identifier: NCT00278629).
Subcutaneous immunoglobulin therapy
IVIg therapy has a number of limitations, particularly related to systemic side effects and problems with long-term intravenous access. 25, 59 In many patients, these factors diminish QoL and independence. 59 Subcutaneous immunoglobulin (SCIg) is an alternative treatment option for patients with CIDP who have stabilized on IVIg, and has the potential to address some of these issues. 59 SCIg is a home-based, self-administered route of Ig therapy.
SCIg has been reported to have a favorable systemic side-effect profile and enables closer maintenance of stable serum IgG levels.
A series of small clinical studies and case reports have shown that patients with CIDP who have responded to IVIg can benefit from a switch to SCIg. [60] [61] [62] [63] [64] In some series there is less 'wearing-off' and QoL measures were improved after switching from IVIg to SCIg. In addition, the adverse event profile of SCIg was generally more favorable than that of IVIg. 61, 62, [65] [66] [67] The PATH trial
The PATH (phase 3 subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy) trial (ClinicalTrial.gov identifier: NCT01545076) has evaluated the use of a 20%
SCIg formulation (IgPro20, Hizentra ® , CSL Behring, Pennsylvania, United
States) in CIDP. 68 In this trial, 172 patients who were stabilized on IVIg and demonstrated to be IVIg dependent, were randomized to weekly high-dose SCIg (0.4 g/Kg equivalent to 2 mL/kg), low-dose SCIg (0.2 g/Kg equivalent to 1 mL/kg) or volume-matched placebo for 24 weeks. In the intention-to-treat analysis, the primary endpoint, proportions of patients who had no CIDP relapse or did not withdraw from the study, were 67% of the high-dose group, 61% of the low-dose group, and 37% of the placebo group (p=0.001 and p=0.007 for high-and low-dose versus placebo; Figure 1 ). 68 Time to reach the primary endpoint was significantly longer for both high-and lowdose SCIg versus placebo (p=0.0005 and p=0.007, respectively; Figure 2) but the difference between doses was not significant (p=0.48). 68 Absolute risk reductions for relapse/withdrawal were 30% for high-dose versus placebo (p=0.001), 25% for low-dose versus placebo (p=0.007) and 6% for high-dose versus low-dose (p=0.32). 68 A sensitivity analysis of patients who relapsed only showed lower rates and Medical Research Council (MRC) sum score (p=0.0026). 68 The SCIg 69, 70 Overall, the PATH trial demonstrated that SCIg is a reasonable treatment option for patients already stabilized on IVIg therapy and may be a good choice for patients with systemic side effects from IVIG, difficulty with venous access, and those who have logistical issues scheduling frequent intravenous infusions. Limitations of SCIg therapy relate to the risk of relapse with treatment switch, difficulty administering for patients with limited finger strength, and local injection site reactions. 68, 71, 72 
Comparative studies
Only a few studies have been performed comparing treatments for CIDP.
Short term studies of 6 weeks, comparing IVIg and plasmapheresis and IVIg and prednisone have not shown significant differences, in efficacy or safety. 73, 74 CIDP though is a chronic disease and these short studies do not reflect the safety and efficacy over the course of the disease.
Two different corticosteroid regimens were compared in a cohort of patients with CIDP in the PREDICT (pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy) study (n=40). 75 After 12 years found that cure or long-term remission was achieved in 10/39 (26%) of patients after either one or two courses of pulsed dexamethasone or daily prednisolone. 76 Of the patients who were in remission after initial treatment, half had a relapse (median treatment-free interval 17.5 months versus 11 months, respectively). In 7/12 of patients (56%) who did not respond the diagnosis of CIDP was changed to another condition. This prompted the authors to suggest that in patients who fail to respond to these treatments, an alternative diagnosis should be considered.
Comparing intravenous immunoglobulin with intravenous corticosteroids
Few studies have directly compared IVIg with corticosteroids in CIDP treatment and the relative risks and benefits are consequently not well understood. In the IMC (Immunoglobulin Methylprednisolone for CIDP) study (n=45), during 6 months of treatment, more patients discontinued treatment whilst receiving intravenous methylprednisolone than IVIg (52% versus 13% relative risk: 0.54, 95% CI 0.34-0.87, p=0.0085). 77 After adjustment for sex, age, disease duration, comorbidity, modified
Rankin scale and Overall Neuropathy Limitations Scale (ONLS) scores at enrolment, and previous treatment with IVIg and steroids the difference was still significant. (odds ratio: 7.7, 95% CI 1.7-33.9, p=0.007). The frequency of adverse events was similar in each group (p=0.1606). During the 6-month treatment period, patients who failed to respond were given IVIg as secondary therapy. 78 In the IMC study, after the treatment period ended and a median follow-up of 42 months, 28/32 (87.5%) patients treated with IVIg (either as primary or secondary therapy) had improved compared with 13/24 (54.2%) who received intravenous methylprednisolone (as primary or secondary therapy). 77 This long-term follow-up also showed that a similar proportion Table 2 ). Survival curves Figure 3 .
A post-hoc analysis of patient data from the IMC study found that a pure focal distribution of demyelination at baseline was associated with early deterioration following corticosteroid therapy. 79 Among patients with early deterioration (n=7), 71% showed a pure focal distribution of demyelination compared with 29% with a non-focal distribution (n=26).
In patients with non-early deterioration, however, 19% had pure focal and 81% had a non-focal distribution ( Table 3 ). The analysis also showed that lesser sensory abnormalities may also be associated with a pure focal demyelination pattern. The results suggested that focal/non-focal demyelination patterns could be used predictively in guiding treatment but more investigation is needed. 78 Copyright permission from BMJ. 
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